HEALTHCARE RESOURCE UTILIZATION AND COSTS OF NON-NAïVE PATIENTS INITIATING OCRELIZUMAB VERSUS MODERATE-EFFICACY TREATMENTS FOR MULTIPLE SCLEROSIS: 2-YEAR REAL-WORLD EVIDENCE FROM THE FRENCH OLIDIA STUDY
Author(s)
Xavier Moisset, PhD, MD1, Jonathan Ciron, MD2, Emmanuele Conde Da Silva Fraga, PhD3, Floriane Deygas, MSc4, Guillaume Bourel, MSc3, Paula A. Allier Lechuga, Bsc3, David Pau, MSc3, Alexandre Civet, MSc3, Laurent Suchet, MD5.
1Neurology department, Neuro-Dol, CHU Clermont-Ferrand, Clermont-Ferrand, France, 2Department of Neurology, CRC-SEP, CHU Toulouse, Toulouse, France, 3Roche, Boulogne-Billancourt, France, 4Epimentis, Lyon, France, 5Department of Neurology, Hôpital Européen Marseille, Marseille, France.
1Neurology department, Neuro-Dol, CHU Clermont-Ferrand, Clermont-Ferrand, France, 2Department of Neurology, CRC-SEP, CHU Toulouse, Toulouse, France, 3Roche, Boulogne-Billancourt, France, 4Epimentis, Lyon, France, 5Department of Neurology, Hôpital Européen Marseille, Marseille, France.
OBJECTIVES: To compare 2-year real-world Healthcare Resource Utilization (HCRU) and costs between treatment non-naïve Multiple Sclerosis (MS) patients initiating ocrelizumab (OCR), a high-efficacy treatment, versus moderate-efficacy treatments (MET) in France.
METHODS: This analysis was conducted as part of the real-world retrospective OLIDIA study, using data from the French National Health Data System (SNDS). Adult non-naïve MS patients initiating OCR between February 2019 and December 2020 were matched 1:1 to MET initiators using propensity scores adjusted for baseline sociodemographics, year of treatment initiation, disease severity, number of previous treatments, and comorbidities. HCRU and monthly per-patient costs were evaluated across two consecutive 12-month periods following treatment initiation.
RESULTS: A total of 4,246 matched non-naïve patients were included (2,123 OCR/MET pairs). Across all patient populations, medical and paramedical contacts were near-universal (>97% of patients); of these, general practitioner visits (>86%) and out-hospital laboratory tests (>85%) were most common.For OCR patients, the monthly rate of dispensed corticosteroid boxes, indicative of acute relapse incidence, was lower compared to MET in Year 1 (Incidence Rate Ratio [IRR]=0.81 [0.65-1.00], p=0.051) and significantly lower in Year 2 (IRR=0.79 [0.63-0.99], p=0.04). Furthermore, among patients susceptible to at least one non-infusion MS-related hospitalization, hospitalization rates did not differ between OCR and MET patients in Year 1, but by Year 2 were 41% lower with OCR than with MET (IRR=0.59 [0.42-0.82], p<0.01).
CONCLUSIONS: This real-world data analysis underlined that in treatment non-naïve MS patients, initiating OCR was associated with significantly reduced acute relapses and non-infusion MS-related hospitalization compared to MET.
METHODS: This analysis was conducted as part of the real-world retrospective OLIDIA study, using data from the French National Health Data System (SNDS). Adult non-naïve MS patients initiating OCR between February 2019 and December 2020 were matched 1:1 to MET initiators using propensity scores adjusted for baseline sociodemographics, year of treatment initiation, disease severity, number of previous treatments, and comorbidities. HCRU and monthly per-patient costs were evaluated across two consecutive 12-month periods following treatment initiation.
RESULTS: A total of 4,246 matched non-naïve patients were included (2,123 OCR/MET pairs). Across all patient populations, medical and paramedical contacts were near-universal (>97% of patients); of these, general practitioner visits (>86%) and out-hospital laboratory tests (>85%) were most common.For OCR patients, the monthly rate of dispensed corticosteroid boxes, indicative of acute relapse incidence, was lower compared to MET in Year 1 (Incidence Rate Ratio [IRR]=0.81 [0.65-1.00], p=0.051) and significantly lower in Year 2 (IRR=0.79 [0.63-0.99], p=0.04). Furthermore, among patients susceptible to at least one non-infusion MS-related hospitalization, hospitalization rates did not differ between OCR and MET patients in Year 1, but by Year 2 were 41% lower with OCR than with MET (IRR=0.59 [0.42-0.82], p<0.01).
CONCLUSIONS: This real-world data analysis underlined that in treatment non-naïve MS patients, initiating OCR was associated with significantly reduced acute relapses and non-infusion MS-related hospitalization compared to MET.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE507
Topic
Economic Evaluation, Real World Data & Information Systems
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Neurological Disorders, No Additional Disease & Conditions/Specialized Treatment Areas